ClinicalTrials.gg
CompletedNCT00163475Updated Oct 25, 2016

Efficacy and Safety of Roflumilast Taken in the Morning or Evening in Patients With Stable Asthma (12 to 70 y) (BY217/M2-015)

A Phase 3 interventional study of Roflumilast in Asthma, sponsored by AstraZeneca. Completed at 5 sites in 5 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-25.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
12 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing roflumilast in Asthma — none open to participants now, none under way, none of them phase 3. Roflumilast · Asthma.

Enrollment
4th of 10
511 · median 300
Started
2004
with 3 others
Phase 3
5 of 10
none open now
Registered
3rd of 10
by date
Lead sponsor
8 of 10
AstraZeneca

Among the 10 studies testing roflumilast in Asthma, this one is the 4th largest by enrollment, is one of 4 that started in 2004, is one of 5 in phase 3, and was the 3rd registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 10 studies testing roflumilast in Asthma is open now. The open studies under Asthma, anywhere →

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing roflumilast in Asthma as a file.
02

Study summary

Bronchial asthma is among the world's most prevalent diseases. Roflumilast is a novel, orally active, selective enzyme inhibitor (phosphodiesterase 4 inhibitor), which has shown effectiveness in the treatment of asthma.

The aim of the study is to compare the effect of roflumilast on lung function, symptoms, and use of rescue medication in patients with stable asthma. Roflumilast will be administered orally either in the morning or in the evening at one dose level. The study duration consists of a baseline period (1 to 2 weeks) and a treatment period (6 weeks). The study will provide further data on safety, tolerability, and effectiveness of roflumilast.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • Roflumilast
04

Who can participate

Ages eligible
12 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Written
  • Diagnosis of persistent bronchial asthma (with reference to the Global Initiative for Asthma Guidelines 2002)
  • Baseline 50 - 85% in patients either untreated or receiving e.g. short-acting bronchodilators, DSCG, nedocromil, anticholinergics, long-acting bronchodilators, theophylline/aminophylline, lipoxygenase inhibitors, leukotriene antagonists, alone or in combination
  • Baseline FEV1 60 - 90% in patients receiving not more than 500 mcg BDP-CFC (or equivalent) and/or in combination with any other asthma medication mentioned above
  • No change in the asthma treatment 4 weeks prior to baseline period
  • Patients who, with the exception of asthma, are in good health

Main Exclusion Criteria:

  • Poorly controlled asthma: requirement of a course of oral and/or parenteral glucocorticosteroids 4 weeks prior to the baseline, or admission to hospital for asthma (including treatment in an emergency room) 4 weeks prior to the baseline period, or asthma exacerbation in the last 4 weeks prior to baseline period
  • Patient using regularly >8 puffs/day rescue medication prior to baseline
  • History of lower airway infection in the last 4 weeks prior to baseline period
  • Diagnosis of and/or other relevant lung diseases
  • Heavy smoker: currently: >20 cigarettes/day and/or >10 pack years, ex-smoker: with a smoking history of ≥10 pack years
  • abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
  • Liver insufficiency ( A or worse)
  • Active hepatitis
  • Known infection with
  • Diagnosis or history of cancer (other than basal cell carcinoma) or recurrence within 5 years prior to study start
  • Alcohol and/or drug abuse
  • Suspected and/or to any ingredients of the study medication (roflumilast) or rescue medication
  • Pregnancy or patient of who is not using reliable method of
  • Patients not able to follow study procedures, e.g. due to language problems, psychological disorders
  • Suspected inability or unwillingness to comply with the study procedures
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
511 participants

Interventions

06

What researchers measure

Primary outcomes

  1. mean change from randomization to endpoint in forced expiratory volume in one second.

Secondary outcomes

  1. forced expiratory vital capacity

  2. peak expiratory flow

  3. morning and evening peak expiratory flow (patient's diary)

  4. symptom score and use of rescue medication (patient's diary)

  5. Asthma Control Questionnaire (ACQ)

  6. proportion of symptom-free days / rescue medication-free days asthma exacerbations.

07

Study locations

5 sites
  • ALTANA Pharma
    Cities in Australia, Australia
  • ALTANA Pharma
    Cities in Belgium, Belgium
  • ALTANA Pharma
    Cities in France, France
  • ALTANA Pharma
    Cities in South Africa, South Africa
  • ALTANA Pharma
    Cities in Spain, Spain
08

References and documents

Publications

  • Bateman ED, Bousquet J, Aubier M, Bredenbroker D, O'Byrne PM. Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies. Pulm Pharmacol Ther. 2015 Dec;35 Suppl:S11-9. doi: 10.1016/j.pupt.2015.10.002. Epub 2015 Oct 8. PubMed 26456372 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2004, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 14, 2005
Start
May 2004
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
Oct 25, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00163475
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 14, 2005
Start date
May 2004
Primary completion
Aug 2005
Completion
Aug 2005
Last update
Oct 25, 2016

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion